Natural antibiotic susceptibility of recently established coryneform bacteria

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 20, Issue 5, 2001, Pages 315-323

  Troxler, R ^a   Funke, G ^b   Von Graevenitz, A ^a   Stock, I ^c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Gartner/Colleagues Laboratories   (Germany)

^c Pharmazeutische Mikrobiologie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; FLEROXACIN; FOLIC ACID ANTAGONIST; FOSFOMYCIN; FUSIDIC ACID; GLYCOPEPTIDE; LINCOSAMIDE DERIVATIVE; MACROLIDE; NITROFURANTOIN; NORFLOXACIN; PENICILLIN DERIVATIVE; PIPEMIDIC ACID; RIFAMPICIN; STREPTOGRAMIN DERIVATIVE; SULFAMETHOXAZOLE; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; TRIMETHOPRIM;

ACTINOMYCETALES; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BREVIBACTERIUM CASEI; CONTROLLED STUDY; CULTURE MEDIUM; DATA BASE; DERMABACTER HOMINIS; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; TURICELLA OTITIDIS;

EID: 0034752157     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960100503     Document Type: Article

References (24)

1. Clinical microbiology of coryneform bacteria
2. Brevibacterium casei sp. nov. and Brevibacterium epidermidis sp. nov.
3. Differentiation of Brevibacterium spp. encountered in clinical specimens
4. Human infections caused by Brevibacterium casei, formerly CDC groups B-1 and B-3
5. Broviac catheter-related bacteraemias due to unusual pathogens in children with cancer: Case report with literature review
6. Recurrent bacteremia due to Brevibacterium casei in an immunocompromised patient
7. Taxonomic studies on some human cutaneous coryneform bacteria: Description of Dermabacter hominis gen. nov., sp. nov.
8. Characteristics of CDC group 3 and group 5 coryneform bacteria isolated from clinical specimens and assignment to the genus Dermabacter
9. Recognition of Dermabacter hominis, formerly CDC fermentative coryneform group 3 and group 5, as a potential human pathogen
10. Cerebral Dermabacter hominis abscess
11. Turicella otitidis gen. nov., sp. nov., a coryneform bacterium isolated from patients with otitis media
12. Identification of Turicella otitidis isolated from a patient with otorrhea associated with surgery: Differentiation from Corynebacterium afermentans and Corynebacterium auris
13. Natural antibiotic susceptibility of Providencia stuartii, Providencia rettgeri, Providencia alcalifaciens and Providencia rustigianii strains
14. An in-vitro study of the antimicrobial susceptibilities of Yersinia enterocolitica and the definition of a database
15. Natural β-lactam susceptibility and mechanisms of β-lactam resistance in Yersinia enterocolitica strains
16. Antimicrobial susceptibility patterns of some recently established coryneform bacteria
17. Statement
18. Antimicrobial susceptibility testing in Sweden. Part 3: Methodology for susceptibility testing
19. Antibiotic susceptibility testing (agar disk diffusion and agar dilution) of clinical isolates of Corynebacterium jeikeium
20. Aztreonam
21. Isolation of coryneform group JK from clinical specimens with a semiselective medium
22. The antimicrobial activity of fusidic acid